Fatal Familial Insomnia Prion Disease: An In-Depth Guide for Healthcare Professionals

Introduction

Fatal familial insomnia (FFI) prion disease represents an exceptionally rare and devastating inherited neurodegenerative condition. This progressive disorder, rooted in a mutation of the prion protein (PRNP) gene, is characterized by relentless insomnia and a cascade of debilitating symptoms. As a Fatal Familial Insomnia Prion Disease, FFI is categorized within a group of disorders caused by misfolded prion proteins, leading to significant neuronal damage, particularly in the thalamus. The hallmarks of this condition include intractable insomnia, which is aggressively progressive and followed by severe autonomic dysfunction, cognitive impairment, motor abnormalities, and endocrine disruptions. Given its incurable nature and average disease duration of only 18 months, fatal familial insomnia prion disease invariably leads to death, posing significant challenges for both patients and healthcare providers. Diagnosis relies heavily on clinical evaluation, emphasizing the critical role of detailed patient history and neurological examination. Current management strategies for fatal familial insomnia prion disease are primarily focused on symptomatic treatment and palliative care, aiming to alleviate suffering and enhance the quality of remaining life. This comprehensive guide is designed for healthcare professionals to improve their understanding of fatal familial insomnia prion disease, encompassing diagnostic approaches, management strategies, and the importance of interprofessional collaboration to optimize patient outcomes in this complex and rare disease.

Etiology of Fatal Familial Insomnia Prion Disease

Fatal familial insomnia prion disease belongs to a cluster of genetic human prion diseases. This group also includes conditions such as familial Creutzfeldt-Jakob disease, prion protein amyloidosis, Gerstmann-Sträussler-Scheinker syndrome, and Huntington disease-like 1. The underlying cause of fatal familial insomnia prion disease is an autosomal dominant mutation within the PRNP gene, specifically at codon 178. This gene, located on the short arm of chromosome 20 (20p13), is responsible for producing the normal prion protein, PrPC. Inherited mutations in the PRPN gene account for approximately 10% to 15% of all prion disease diagnoses. In the context of fatal familial insomnia prion disease, the specific genetic alteration is termed D178N, which is often linked to the M129 genotype in the pPrPC gene. While the precise timing of disease onset remains unclear, evidence suggests that the development of fatal familial insomnia prion disease is triggered when a critical threshold of normal prion protein converts to the pathogenic, misfolded prion protein. This accumulation of faulty prion protein initiates the neurodegenerative processes characteristic of fatal familial insomnia prion disease.

Epidemiology of Fatal Familial Insomnia Prion Disease

Globally, fatal familial insomnia prion disease remains exceptionally rare, with only hundreds of documented cases. The majority of these cases have been reported in European and Asian populations, with a recent notable increase in reported cases from China. A comprehensive study identified 131 patients with fatal familial insomnia prion disease, with a slight male predominance (72 men and 57 women). The average age at disease onset was 47.5 years, with a wide range from 17 to 76 years. Among those patients, 106 had died, with an average disease duration of 13.2 months, ranging from 2 to 48 months. Geographical variations in the clinical presentation of fatal familial insomnia prion disease and their correlation with genetic backgrounds are areas of ongoing research. A smaller study indicated that polymorphism at codon 129 of the PRNP gene might influence the phenotypic expression of FFI. For example, Asian patients were observed to have a higher frequency of motor symptoms, sleep-related breathing difficulties, and laryngeal stridor. Conversely, other clusters exhibited prominent hypertension, excessive sweating, and weight loss. Interestingly, diplopia (double vision) and myoclonus were reported less frequently in Asian patients compared to other ethnic groups. Overall, genetic prion diseases, including fatal familial insomnia prion disease, are exceedingly rare, with an annual incidence of 1 to 1.5 new cases per million people. Hereditary prion diseases constitute about 10% of all prion disease cases, emphasizing the rarity of fatal familial insomnia prion disease within this already uncommon group of disorders.

Pathophysiology of Fatal Familial Insomnia Prion Disease

The pathophysiology of fatal familial insomnia prion disease is characterized by specific neuropathological changes, primarily neuronal loss and gliosis, particularly affecting the thalamus. The thalamus is a critical brain structure involved in sensory and motor signal relay, consciousness, and sleep regulation. These pathological changes in the thalamus directly contribute to the core clinical features of fatal familial insomnia prion disease, notably severe sleep disturbances and autonomic dysfunction. The progression of these pathological changes to other brain regions accounts for the diverse range of clinical manifestations observed in individuals affected by fatal familial insomnia prion disease.

Studies have indicated that the parietal, temporal, and frontal lobes show a greater degree of involvement compared to the occipital lobe in fatal familial insomnia prion disease. Furthermore, the cerebral cortex is almost invariably affected, with the extent of spongiosis and astrogliosis correlating positively with the duration of the disease. However, the deposition pattern of prion protein in fatal familial insomnia prion disease shows an early predilection for the brainstem and thalamus, with the thalamus experiencing the most pronounced degenerative changes. The underlying mechanisms for this selective vulnerability remain poorly understood but are likely responsible for the varied symptomatology seen in fatal familial insomnia prion disease.

Histopathology of Fatal Familial Insomnia Prion Disease

Histopathological examination in fatal familial insomnia prion disease reveals a complex relationship between prion protein deposits, their protease-resistant forms, and the severity of tissue damage. Western blot and immunocytochemistry studies on human brain tissue have demonstrated a disconnection between the amount and location of prion protein deposits and the degree of histopathological changes. In one study analyzing the cerebellar cortex of FFI patients, prion protein deposits were found to be heavily concentrated in the molecular layer, exhibiting a distinct patchy and strip-like pattern oriented perpendicular to the surface. In another patient from the same study, a single neuron within the inferior olivary nuclei displayed abundant protease-resistant prion protein deposits within vacuoles, similar to changes observed in brainstem neurons in bovine spongiform encephalopathy. These findings highlight the intricate and regionally specific nature of prion protein deposition and its pathological consequences in fatal familial insomnia prion disease.

History and Physical Examination for Fatal Familial Insomnia Prion Disease

The onset of symptoms in fatal familial insomnia prion disease typically occurs between 20 and 61 years of age, with an average age of onset around 50 years. Fatal familial insomnia prion disease commonly presents with varied clinical phenotypes, underscored by significant neuronal loss and gliosis, especially within the thalamus. A thorough history and neurological examination are paramount in diagnosing fatal familial insomnia prion disease, as it remains primarily a clinical diagnosis. When evaluating a patient for possible fatal familial insomnia prion disease, several key diagnostic clinical features should be considered:

Diagnostic Clinical Features of Fatal Familial Insomnia Prion Disease

In 2022, an international consensus group established diagnostic clinical criteria to aid in differentiating fatal familial insomnia prion disease from other conditions with overlapping symptoms and to facilitate earlier diagnosis. The duration of the following core symptoms is typically indicative of fatal familial insomnia prion disease:

• Organic sleep disturbances: These include intractable insomnia, agrypnia excitata (a state of near-complete sleeplessness with motor and autonomic hyperactivity), with or without laryngeal stridor, sleep apnea, or involuntary movements during sleep such as hypnic jerks and restless sleep characterized by frequent body position changes.
• Neurologic and mental health impairment: This category encompasses rapidly progressive dementia, ataxia, myoclonus, hallucinations, delusions, or personality changes including depression, anxiety, apathy, and confusion.
• Progressive autonomic and systemic abnormalities: These may manifest as hypertension, tachycardia, irregular breathing, hyperthermia, excessive sweating, or significant weight loss (greater than 10 kg within the last 6 months).

In addition to these core clinical features, the following factors can further support a diagnosis of fatal familial insomnia prion disease:

• Family history of organic insomnia symptoms, suggesting a genetic predisposition.
• Probable organic insomnia, evidenced by disruptions in circadian rhythm, sleep fragmentation, reduced total sleep time, or sleep-wake cycle reversal, possibly accompanied by involuntary movements documented on video polysomnography.

Evaluation and Diagnosis of Fatal Familial Insomnia Prion Disease

While the diagnosis of fatal familial insomnia prion disease is primarily clinical, various diagnostic studies are essential to support the clinical impression and to exclude other potential conditions.

Diagnostic Studies for Fatal Familial Insomnia Prion Disease

• Initial Blood Work: A comprehensive initial evaluation should include a complete blood count (CBC), erythrocyte sedimentation rate (ESR), serum chemistry, liver function tests (LFTs), ammonia levels, and blood cultures, particularly to rule out bacterial infections that might mimic some symptoms.
• Tests for Reversible Cognitive Decline: To exclude reversible causes of cognitive impairment, thyroid function tests (TFTs), vitamin B-12 and folate levels, along with tests for neurosyphilis and human immunodeficiency virus (HIV) should be performed.
• Polysomnography (PSG): PSG is a crucial diagnostic tool that can reveal characteristic sleep abnormalities in fatal familial insomnia prion disease, such as a reduction in total sleep time and dysfunctional transitions between sleep stages. Specifically, PSG typically shows reduced REM sleep, decreased sleep efficiency, and diminished slow-wave sleep.
• Electroencephalogram (EEG): While periodic sharp-wave complexes (PSWC) on EEG are suggestive of prion disease, they are not commonly observed in genetic forms like fatal familial insomnia prion disease. PSWC are more frequently seen in prion diseases with pronounced spongiform degeneration and a clinical presentation similar to Creutzfeldt-Jakob disease. In fatal familial insomnia prion disease, EEG findings are often non-specific, potentially showing generalized slowing without periodic sharp-wave complexes.
• Cerebrospinal Fluid (CSF) Analysis: CSF biomarkers, such as the 14-3-3 protein, are not specific to fatal familial insomnia prion disease and can be elevated in various conditions causing neuronal death. Therefore, CSF analysis has limited diagnostic specificity for FFI.

Imaging Studies for Fatal Familial Insomnia Prion Disease

• Computed Tomography (CT) and Magnetic Resonance Imaging (MRI): CT and conventional MRI are generally of limited diagnostic value in fatal familial insomnia prion disease. However, they are important for excluding other neurological pathologies that could mimic FFI symptoms.
• Diffusion-weighted MRI: Diffusion MRI may reveal reduced thalamic diffusion in fatal familial insomnia prion disease, which is attributed to gliosis. Atrophic changes in the thalamus and other brain regions may become more apparent as the disease progresses.
• Fluorodeoxyglucose Positron Emission Tomography (FDG-PET): FDG-PET imaging can be a valuable tool in diagnosing fatal familial insomnia prion disease. PET scans often demonstrate hypometabolism in the thalamic and cingulate regions, with a tendency to spare the occipital lobe. This pattern of metabolic reduction can support the clinical diagnosis.

Molecular Genetic and Histopathological Testing

• Molecular Genetic Testing: Genetic testing is critical for confirming the diagnosis of fatal familial insomnia prion disease. Targeted analysis for the pathogenic variant of the PRNP gene, specifically the D178N mutation, or full gene sequencing should be performed in suspected patients.
• Histopathological Testing: Brain biopsies are not typically diagnostic for fatal familial insomnia prion disease and are rarely performed. However, in some cases, a brain biopsy may be considered to rule out other neurological diseases, especially if the clinical or genetic findings are atypical.

Diagnostic Approach to Fatal Familial Insomnia Prion Disease

Following comprehensive genetic counseling, polysomnography and genetic testing are strongly recommended when fatal familial insomnia prion disease is suspected. Targeted screening for the D178N mutation in the PRNP gene is particularly useful for early diagnosis. While clinical findings provide crucial initial diagnostic information, genetic testing and counseling are essential to confirm the diagnosis and to identify potential risks for family members. Early and accurate diagnosis through genetic screening and clinical assessment is vital for patient management and family counseling in fatal familial insomnia prion disease.

Utilizing the 2022 international group diagnostic criteria, the likelihood of fatal familial insomnia prion disease can be categorized. This diagnostic approach integrates core clinical and supportive features with diagnostic study findings and exclusionary factors:

• Exclusionary Features:
  • Periodic sharp wave complexes (PSWC) on EEG.
  • Hyperintense signals in the caudate nucleus and putamen or in two or more cortical regions on MRI.
  • Clinical presentation that is better explained by alternative diagnoses.
• Diagnostic Studies (Confirmatory): Positive molecular genetic testing for a pathogenic PRNP mutation, particularly D178N.
• Probability of FFI Diagnosis Based on Criteria:
  • Possible FFI: Presence of 2 out of 3 core clinical features without any exclusionary features.
  • Probable FFI: Presence of 2 out of 3 core clinical features, plus at least one supportive feature, and no exclusionary features.
  • Definite FFI: Presence of 2 out of 3 core clinical features and positive confirmatory diagnostic studies (genetic testing).

Treatment and Management of Fatal Familial Insomnia Prion Disease

The treatment and management of fatal familial insomnia prion disease are primarily palliative, focusing on symptomatic relief and supportive care, as there is currently no cure for this fatal condition. Various treatment modalities have been explored, as documented in medical literature:

• Medication Review: It is crucial to discontinue any medications that could potentially exacerbate confusion, memory problems, and insomnia.
• Sedative Ineffectiveness: Patients with fatal familial insomnia prion disease typically show a poor response to conventional sedatives. Studies have reported that barbiturates and benzodiazepines have minimal to no effect on EEG activity in FFI patients, indicating their limited efficacy in managing insomnia in this condition.
• Nutritional Support: Swallowing difficulties may arise as the disease progresses, potentially necessitating the placement of a feeding tube to ensure adequate nutritional intake and prevent aspiration.
• Gamma-Hydroxybutyrate (GHB): Case reports have investigated the use of gamma-hydroxybutyrate (GHB) in fatal familial insomnia prion disease. GHB administration has been observed to induce slow-wave sleep (SWS) in some patients with FFI, suggesting a potential, though limited, role in managing sleep disturbances.
• Investigational Compounds: Several compounds, including pentosane polysulfate, quinacrine, and amphotericin B, have been studied as potential treatments for prion diseases, including fatal familial insomnia prion disease. However, clinical trials have yielded inconclusive results, and none of these treatments have demonstrated significant therapeutic benefit.
• Doxycycline Prevention Trial: A clinical trial is ongoing in Italy to evaluate the preventive potential of doxycycline in individuals who are carriers of the PRNP D178N/M129 mutation, and therefore at high risk of developing fatal familial insomnia prion disease. The study involves administering doxycycline 100 mg orally daily for 10 years to mutation carriers and comparing outcomes to a control group of non-carrier family members. This trial aims to determine if doxycycline can delay or prevent the onset of fatal familial insomnia prion disease in at-risk individuals. Results from this trial are pending.
• Immunotherapy Research: Immunotherapy approaches are being explored as potential treatments for prion diseases, including fatal familial insomnia prion disease, with promising results in in vitro and in vivo animal studies, as well as early clinical trials. The main types of immunotherapy under investigation include antibody vaccines, dendritic cell vaccines, and adoptive transfer of physiological prion protein-specific CD4(+) T-lymphocytes. Antibody vaccines are designed to target unique epitopes specifically displayed on the misfolded prion protein (PrP(Sc)), aiming to selectively neutralize the pathogenic form.
• Psychosocial Support and Hospice Care: Psychosocial therapy is essential for both the patient and their family, providing emotional and psychological support throughout the disease course. Hospice care should be integrated early in the management plan to provide comprehensive palliative care, focusing on maximizing comfort and quality of life for the patient and support for the family during the terminal stages of fatal familial insomnia prion disease.

Differential Diagnosis of Fatal Familial Insomnia Prion Disease

When evaluating patients suspected of having fatal familial insomnia prion disease, it is crucial to consider other prion diseases due to overlapping symptomatology. The differential diagnosis should include:

• Sporadic Creutzfeldt-Jakob disease (sCJD) and familial Creutzfeldt-Jakob disease (fCJD): While clinically and pathologically similar, sCJD is typically more aggressive and has a later onset. Both sCJD and fCJD predominantly present with memory problems and confusion, followed by myoclonus and ataxia. Histopathologically, spongiform degeneration and astrogliosis are more widespread and pronounced in sCJD and fCJD compared to fatal familial insomnia prion disease.
• Sporadic Fatal Insomnia (sFI): Sporadic fatal insomnia presents with clinical and histopathological features that closely mimic fatal familial insomnia prion disease but lacks the genetic mutation associated with FFI. Like other neurodegenerative diseases, sFI lacks a precise animal model and effective therapeutic interventions, making disease modeling crucial for understanding its pathogenic mechanisms.
• Gerstmann-Sträussler-Scheinker syndrome (GSS): GSS typically manifests with cerebellar dysfunction, with minimal sleep disturbance. Cognitive dysfunction is generally less prominent and more likely to occur in later stages. GSS is also inherited in an autosomal dominant manner, with high penetrance due to various point mutations and insertions in the PRNP gene.
• Variably Protease-Sensitive Prionopathy (VPSPr): VPSPr can present with a range of symptoms, including aphasia and behavioral disturbances, and is best diagnosed through histopathological examination.
• Non-Prion Differential Diagnoses: It is also essential to rule out non-prion conditions that can mimic aspects of fatal familial insomnia prion disease, including:
  • Lithium toxicity
  • Familial myoclonic dementia
  • Diffuse Lewy body disease
  • Chronic meningitis
  • Dementia as a paraneoplastic syndrome
  • Dementia in motor neuron disease
  • Nonherpes viral encephalitis
  • Hashimoto encephalopathy (steroid-responsive encephalopathy associated with autoimmune thyroiditis [SREAT])
  • Limbic encephalitis and other paraneoplastic syndromes

Furthermore, it is important to exclude reversible causes of dementia, such as herpes encephalitis, paraneoplastic syndromes including limbic encephalitis, Hashimoto encephalitis, lithium poisoning, chronic meningitis, HIV encephalopathy, and hydrocephalus. Neurodegenerative diseases like Alzheimer’s disease, Pick disease, corticobasal degeneration, multiple system atrophy, frontotemporal dementia, and familial myoclonic dementia should also be considered in the differential diagnosis, even though they typically progress more slowly.

Staging of Fatal Familial Insomnia Prion Disease

Fatal familial insomnia prion disease is often described in four progressive stages:

• Stage 1: Characterized by the subacute onset of insomnia, which gradually worsens over several months. Psychiatric symptoms such as phobias, paranoia, and panic attacks may emerge. Patients might report vivid, lucid dreams during this stage.
• Stage 2: Over the next five months, psychiatric symptoms intensify, insomnia worsens, and hallucinations may develop. Autonomic dysfunction becomes evident, manifesting as sympathetic hyperactivity (e.g., increased heart rate, sweating).
• Stage 3: This stage is relatively short, lasting approximately three months, and is dominated by total insomnia and complete disruption of the sleep-wake cycle.
• Stage 4: The final stage can extend for six months or longer and is marked by rapid cognitive decline and dementia. Patients lose the ability to move or speak voluntarily, progressing to coma and ultimately death.

Prognosis of Fatal Familial Insomnia Prion Disease

Fatal familial insomnia prion disease has a uniformly poor prognosis. The disease course typically ranges from 7 to 36 months, with an average duration of approximately 18 months from symptom onset to death. Genetic factors, such as homozygosity for the Met-Met mutation at codon 129 of the PRNP gene, have been associated with a shorter mean survival time compared to heterozygosity (Met-Val) at the same codon. Fatal familial insomnia prion disease is invariably fatal, highlighting the urgent need for effective therapies and improved palliative strategies.

Complications of Fatal Familial Insomnia Prion Disease

Fatal familial insomnia prion disease is universally fatal, and patients experience a wide array of complications spanning autonomic, cognitive, motor, and endocrine systems. These complications are detailed in the History and Physical section and reflect the widespread neurodegeneration caused by the prion pathology.

Deterrence and Patient Education for Fatal Familial Insomnia Prion Disease

Given the devastating nature of fatal familial insomnia prion disease, comprehensive patient and family education is paramount. Healthcare providers should thoroughly inform patients and their families about the invariably fatal course of the disease. It is essential to communicate honestly about the current limitations in treatment options while also providing updates on ongoing research and potential future therapies. Genetic counseling should be offered to family members, as fatal familial insomnia prion disease is an inherited condition, allowing them to understand their risk and make informed decisions about genetic testing and family planning.

Enhancing Healthcare Team Outcomes in Fatal Familial Insomnia Prion Disease

Effective management of fatal familial insomnia prion disease necessitates a collaborative, interprofessional healthcare team. This team should include sleep specialists, neurologists, psychiatrists, psychologists, social workers, palliative care nurses, and hospice care professionals. Early involvement of hospice care is crucial to provide optimal support during the advanced stages of the disease. Psychosocial counseling for family members is also vital to address the significant emotional and practical challenges associated with caring for a loved one with fatal familial insomnia prion disease. Effective communication and coordination among team members are essential to delivering holistic care, emphasizing compassionate end-of-life support and addressing the complex medical, psychological, and social needs of patients and their families affected by fatal familial insomnia prion disease.

Review Questions

(Note: Review questions are present in the original article on the website provided. Please refer to the original article for review questions)

References

1.Nafe R, Arendt CT, Hattingen E. Human prion diseases and the prion protein – what is the current state of knowledge? Transl Neurosci. 2023 Jan 01;14(1):20220315. [PMC free article: PMC10579786] [PubMed: 37854584]

2.Bagyinszky E, Giau VV, Youn YC, An SSA, Kim S. Characterization of mutations in PRNP (prion) gene and their possible roles in neurodegenerative diseases. Neuropsychiatr Dis Treat. 2018;14:2067-2085. [PMC free article: PMC6097508] [PubMed: 30147320]

3.Medori R, Montagna P, Tritschler HJ, LeBlanc A, Cortelli P, Tinuper P, Lugaresi E, Gambetti P. Fatal familial insomnia: a second kindred with mutation of prion protein gene at codon 178. Neurology. 1992 Mar;42(3 Pt 1):669-70. [PubMed: 1347910]

4.Schenkein J, Montagna P. Self management of fatal familial insomnia. Part 1: what is FFI? MedGenMed. 2006 Sep 14;8(3):65. [PMC free article: PMC1781306] [PubMed: 17406188]

5.Montagna P, Cortelli P, Avoni P, Tinuper P, Plazzi G, Gallassi R, Portaluppi F, Julien J, Vital C, Delisle MB, Gambetti P, Lugaresi E. Clinical features of fatal familial insomnia: phenotypic variability in relation to a polymorphism at codon 129 of the prion protein gene. Brain Pathol. 1998 Jul;8(3):515-20. [PMC free article: PMC8098256] [PubMed: 9669701]

6.Zerr I, Schmitz M. Genetic Prion Disease. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. University of Washington, Seattle; Seattle (WA): Mar 27, 2003. [PubMed: 20301407]

7.Chen C, Dong XP. Epidemiological characteristics of human prion diseases. Infect Dis Poverty. 2016 Jun 02;5(1):47. [PMC free article: PMC4890484] [PubMed: 27251305]

8.Zhang J, Chu M, Tian Z, Xie K, Cui Y, Liu L, Meng J, Yan H, Ji YM, Jiang Z, Xia TX, Wang D, Wang X, Zhao Y, Ye H, Li J, Wang L, Wu L. Clinical profile of fatal familial insomnia: phenotypic variation in 129 polymorphisms and geographical regions. J Neurol Neurosurg Psychiatry. 2022 Mar;93(3):291-297. [PMC free article: PMC8862016] [PubMed: 34667102]

9.Tinuper P, Montagna P, Medori R, Cortelli P, Zucconi M, Baruzzi A, Lugaresi E. The thalamus participates in the regulation of the sleep-waking cycle. A clinico-pathological study in fatal familial thalamic degeneration. Electroencephalogr Clin Neurophysiol. 1989 Aug;73(2):117-23. [PubMed: 2473878]

10.Montagna P. Fatal familial insomnia and the role of the thalamus in sleep regulation. Handb Clin Neurol. 2011;99:981-96. [PubMed: 21056239]

11.Almer G, Hainfellner JA, Brücke T, Jellinger K, Kleinert R, Bayer G, Windl O, Kretzschmar HA, Hill A, Sidle K, Collinge J, Budka H. Fatal familial insomnia: a new Austrian family. Brain. 1999 Jan;122 ( Pt 1):5-16. [PubMed: 10050890]

12.Krasnianski A, Bartl M, Sanchez Juan PJ, Heinemann U, Meissner B, Varges D, Schulze-Sturm U, Kretzschmar HA, Schulz-Schaeffer WJ, Zerr I. Fatal familial insomnia: Clinical features and early identification. Ann Neurol. 2008 May;63(5):658-61. [PubMed: 18360821]

13.Plazzi G, Schutz Y, Cortelli P, Provini F, Avoni P, Heikkila E, Tinuper P, Solieri L, Lugaresi E, Montagna P. Motor overactivity and loss of motor circadian rhythm in fatal familial insomnia: an actigraphic study. Sleep. 1997 Sep;20(9):739-42. [PubMed: 9406326]

14.Lugaresi E, Medori R, Montagna P, Baruzzi A, Cortelli P, Lugaresi A, Tinuper P, Zucconi M, Gambetti P. Fatal familial insomnia and dysautonomia with selective degeneration of thalamic nuclei. N Engl J Med. 1986 Oct 16;315(16):997-1003. [PubMed: 3762620]

15.Baldelli L, Provini F. Fatal familial insomnia and Agrypnia Excitata: Autonomic dysfunctions and pathophysiological implications. Auton Neurosci. 2019 May;218:68-86. [PubMed: 30890351]

16.Gallassi R, Morreale A, Montagna P, Gambetti P, Lugaresi E. “Fatal familial insomnia”: neuropsychological study of a disease with thalamic degeneration. Cortex. 1992 Jun;28(2):175-87. [PubMed: 1499304]

17.Cortelli P, Fabbri M, Calandra-Buonaura G, Capellari S, Tinuper P, Parchi P, Lugaresi E. Gait disorders in fatal familial insomnia. Mov Disord. 2014 Mar;29(3):420-4. [PubMed: 24375448]

18.Gallassi R, Morreale A, Montagna P, Cortelli P, Avoni P, Castellani R, Gambetti P, Lugaresi E. Fatal familial insomnia: behavioral and cognitive features. Neurology. 1996 Apr;46(4):935-9. [PubMed: 8780067]

19.Montagna P, Cortelli P, Gambetti P, Lugaresi E. Fatal familial insomnia: sleep, neuroendocrine and vegetative alterations. Adv Neuroimmunol. 1995;5(1):13-21. [PubMed: 7795890]

20.Chu M, Xie K, Zhang J, Chen Z, Ghorayeb I, Rupprecht S, Reder AT, Garay A, Honda H, Nagayama M, Shi Q, Zhan S, Nan H, Zhang J, Guan H, Cui L, Guo Y, Rosa-Neto P, Gauthier S, Wang J, Dong X, Wu L. Proposal of new diagnostic criteria for fatal familial insomnia. J Neurol. 2022 Sep;269(9):4909-4919. [PMC free article: PMC9363306] [PubMed: 35501502]

21.Cortelli P, Perani D, Montagna P, Gallassi R, Tinuper P, Provini F, Avoni P, Ferrillo F, Anchisi D, Moresco RM, Fazio F, Parchi P, Baruzzi A, Lugaresi E, Gambetti P. Pre-symptomatic diagnosis in fatal familial insomnia: serial neurophysiological and 18FDG-PET studies. Brain. 2006 Mar;129(Pt 3):668-75. [PubMed: 16399807]

22.Reder AT, Mednick AS, Brown P, Spire JP, Van Cauter E, Wollmann RL, Cervenàkovà L, Goldfarb LG, Garay A, Ovsiew F. Clinical and genetic studies of fatal familial insomnia. Neurology. 1995 Jun;45(6):1068-75. [PubMed: 7783865]

23.Zerr I. Therapeutic trials in human transmissible spongiform encephalo-pathies: recent advances and problems to address. Infect Disord Drug Targets. 2009 Feb;9(1):92-9. [PubMed: 19200019]

24.Forloni G, Tettamanti M, Lucca U, Albanese Y, Quaglio E, Chiesa R, Erbetta A, Villani F, Redaelli V, Tagliavini F, Artuso V, Roiter I. Preventive study in subjects at risk of fatal familial insomnia: Innovative approach to rare diseases. Prion. 2015;9(2):75-9. [PMC free article: PMC4601344] [PubMed: 25996399]

25.Burchell JT, Panegyres PK. Prion diseases: immunotargets and therapy. Immunotargets Ther. 2016;5:57-68. [PMC free article: PMC4970640] [PubMed: 27529062]

26.Medori R, Tritschler HJ, LeBlanc A, Villare F, Manetto V, Chen HY, Xue R, Leal S, Montagna P, Cortelli P. Fatal familial insomnia, a prion disease with a mutation at codon 178 of the prion protein gene. N Engl J Med. 1992 Feb 13;326(7):444-9. [PMC free article: PMC6151859] [PubMed: 1346338]

27.Zerr I, Kallenberg K, Summers DM, Romero C, Taratuto A, Heinemann U, Breithaupt M, Varges D, Meissner B, Ladogana A, Schuur M, Haik S, Collins SJ, Jansen GH, Stokin GB, Pimentel J, Hewer E, Collie D, Smith P, Roberts H, Brandel JP, van Duijn C, Pocchiari M, Begue C, Cras P, Will RG, Sanchez-Juan P. Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain. 2009 Oct;132(Pt 10):2659-68. [PMC free article: PMC2759336] [PubMed: 19773352]

28.Cracco L, Appleby BS, Gambetti P. Fatal familial insomnia and sporadic fatal insomnia. Handb Clin Neurol. 2018;153:271-299. [PubMed: 29887141]

29.Hainfellner JA, Brantner-Inthaler S, Cervenáková L, Brown P, Kitamoto T, Tateishi J, Diringer H, Liberski PP, Regele H, Feucht M. The original Gerstmann-Sträussler-Scheinker family of Austria: divergent clinicopathological phenotypes but constant PrP genotype. Brain Pathol. 1995 Jul;5(3):201-11. [PubMed: 8520719]

30.Yang TW, Park B, Kim KT, Jun JS, Kim YS, Lee ST, Jung KH, Chu K, Lee SK, Jung KY. Fatal familial insomnia presenting with agrypnia excitata and very low atonia index level: A case report and literature review. Medicine (Baltimore). 2018 May;97(18):e0646. [PMC free article: PMC6392909] [PubMed: 29718878]

31.Gaudino S, Gangemi E, Colantonio R, Botto A, Ruberto E, Calandrelli R, Martucci M, Vita MG, Masullo C, Cerase A, Colosimo C. Neuroradiology of human prion diseases, diagnosis and differential diagnosis. Radiol Med. 2017 May;122(5):369-385. [PubMed: 28110369]

32.Manix M, Kalakoti P, Henry M, Thakur J, Menger R, Guthikonda B, Nanda A. Creutzfeldt-Jakob disease: updated diagnostic criteria, treatment algorithm, and the utility of brain biopsy. Neurosurg Focus. 2015 Nov;39(5):E2. [PubMed: 26646926]

33.Lindsley CW. Genetic and Rare Disease of the CNS. Part I: Fatal Familial Insomnia (FFI). ACS Chem Neurosci. 2017 Dec 20;8(12):2570-2572. [PubMed: 29258312]

34.Parchi P, Petersen RB, Chen SG, Autilio-Gambetti L, Capellari S, Monari L, Cortelli P, Montagna P, Lugaresi E, Gambetti P. Molecular pathology of fatal familial insomnia. Brain Pathol. 1998 Jul;8(3):539-48. [PMC free article: PMC8098344] [PubMed: 9669705]

35.Montagna P, Gambetti P, Cortelli P, Lugaresi E. Familial and sporadic fatal insomnia. Lancet Neurol. 2003 Mar;2(3):167-76. [PubMed: 12849238]

Disclosure: Zalan Khan declares no relevant financial relationships with ineligible companies.

Disclosure: Abdulghani Sankari declares no relevant financial relationships with ineligible companies.

Disclosure: Pradeep Bollu declares no relevant financial relationships with ineligible companies.